A composition comprising an amount of an anti-oxidant comprising one or more of ubiquinol, MitoQ, vitamin E, vitamin C, ascorbate-2-phosphate, idebenone, pyrroloquinoline quinone (PQQ), N-acetyl-L-cysteine (NAC), palmitate, reduced glutathione, or a C14-C18 saturated fatty acid effective to preserve, e.g., corneal tissue, and methods of using the composition, are provided.

A composition comprising an amount of an anti-oxidant comprising one or more of ubiquinol, MitoQ, vitamin E, vitamin C, ascorbate-2-phosphate, idebenone, pyrroloquinoline quinone (PQQ), N-acetyl-L-cysteine (NAC), palmitate, reduced glutathione, or a C14-C18 saturated fatty acid effective to preserve, e.g., corneal tissue, and methods of using the composition, are provided.

The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antibiotic agents to treat, pre-emptively treat or prevent infectious peritonitis or intra-abdominal infection and reduce the occurrence of local peritonitis or intra-abdominal abscess resulting therefrom by the intraperitoneal administration of the compositions.

The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antibiotic agents to treat, pre-emptively treat or prevent infectious peritonitis or intra-abdominal infection and reduce the occurrence of local peritonitis or intra-abdominal abscess resulting therefrom by the intraperitoneal administration of the compositions.

The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antibiotic agents to treat, pre-emptively treat or prevent infectious peritonitis or intra-abdominal infection and reduce the occurrence of local peritonitis or intra-abdominal abscess resulting therefrom by the intraperitoneal administration of the compositions.

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

The present disclosure provides compositions and methods capable of potentiating the effects of antibiotics against bacterial infections that either have developed, or that possess the potential to develop, antibiotic tolerance. Methods of sensitizing antibiotic tolerant bacteria to antibiotics, as well as pharmaceutical compositions and therapeutic/prophylactic methods directed at antibiotic tolerant bacteria are also provided.

The present disclosure provides compositions and methods capable of potentiating the effects of antibiotics against bacterial infections that either have developed, or that possess the potential to develop, antibiotic tolerance. Methods of sensitizing antibiotic tolerant bacteria to antibiotics, as well as pharmaceutical compositions and therapeutic/prophylactic methods directed at antibiotic tolerant bacteria are also provided.

The present disclosure provides a pharmaceutical composition for preventing or treating sepsis or septic shock comprising P1P or a derivative thereof. The present composition improves the survival rate of mice with sepsis induced by LPS or CLP treatment, as well as reduces the secretion of cytokines. Further, it helps to enhance the proliferation and function of vascular endothelial cells and increases the expression of SIRT1 protein which decreases in a sepsis patient. Accordingly, it can be effectively used in the treatment of sepsis.